The most important thing for investors trading penny stocks is to get in BEFORE the move happens. Once you are in your position, you are not chasing like every other investor. You can let the market do the work and just ride the wave. This is what we do at Insider Financial for our members. We scan the small-cap universe looking for the next big runners. Just this week, we got our members in position on Kitov Pharma (KTOV) before the big move happened. Luckily, we believe the next KTOV is a name that we already have our early subscribers positioned and that is TTOO stock.
We alerted our subscribers about TTOO stock back in March before the run. Now many of our subscribers are asking what’s next after more than 300% gains. In looking at the chart below, there is a gap that needs to be closed at $2.50. If we close the gap and get above $3, it’s blue skies ahead. After all, it was just 2 years ago that TTOO stock was above $9.
About TTOO Stock
First up, here’s a little background info for those that are reading our coverage on TTOO stock for the first time. T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, and the T2ResistanceTM Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2CaurisTM Panel, T2SARS-CoV-2TM Panel, and T2Lyme TM Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, as well as biothreat pathogens.
TTOO stock is currently developing a SARS-CoV-2 test to run on the Company’s proprietary T2Dx Instrument platform and anticipates shipping the first tests to U.S. customers for clinical use as early as the end of this month. The T2SARS-CoV-2 Test is anticipated to be a sample-to-answer test of a nasopharyngeal swab specimen, with a turnaround time of fewer than two hours and a limit of detection of less than 1,000 genomic equivalents per milliliter. Based on significant interest regarding the availability of the T2SARS-CoV-2 Test the Company has received to date, the Company anticipates that there will be demand for the test upon it being made commercially available for clinical use. The Company currently has the resources to manufacture up to 100,000 tests per month and, subject to the success of the Company’s efforts to secure additional non-dilutive funding to support the expansion of manufacturing capacity, estimates that it could potentially ramp to approximately 1,000,000 tests per month.
Why The Excitement Around TTOO Stock?
TTOO stock is the market leader when it comes to detecting sepsis-causing pathogens. Many deaths from Covid-19 mirror deaths from sepsis, which are also largely preventable with better diagnostic tools. Sepsis, the immune system’s out-of-control response to infection, often leads to organ failure and death. In the US alone, sepsis is responsible for more than 250,000 deaths a year and accounts for 1 in 3 hospital-based deaths. Globally, sepsis kills 6 million people a year and leaves many survivors with lingering physical and mental health issues.
Here’s the exciting part. The only FDA cleared system that works directly from blood samples, without upfront culture is the T2Dx from T2 Biosystems, which uses magnetic resonance to deliver results in three to five hours from whole blood samples without isolating the pathogen.
A Revenue-Producing Business
What differentiates TTOO stock from other small-cap biotech plays is that it is already generating sales. In Q1, TTOO stock reported first-quarter total revenue of $2.5 million and product revenue of $1.0 million, representing an increase of 43% and a decrease of 20% respectively, compared to the prior-year period. The company ended the quarter with $36 million in cash and no debt.
TTOO stock was trading above $3 last year when the company was focused solely on sepsis. Now, T2 Biosystems is also focusing on COVID-19 and gearing up to do 1,000,000 tests per month. As a result, we believe the market is mispricing TTOO stock creating a discount entry opportunity. It’s not a question of if a big move is coming in TTOO stock, but when.
As always, good luck to all (except the shorts)!
We will be updating our subscribers as soon as we know more. For the latest updates on NASDAQ:TTOO, sign up today!
Disclosure: We have NO position in NASDAQ:TTOO or any of the stocks mentioned and have NOT been compensated for this article.